Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis

被引：2

作者：

Egan L.J. ^{[1
]}

Sandborn W.J. ^{[1
]}

机构：

[1] Department of Pharmacology, National University of Ireland, University College Hospital, Galway

来源：

Current Gastroenterology Reports | 2005年 / 7卷 / 6期

关键词：

Inflammatory Bowel Disease; Ulcerative Colitis; Infliximab; Adalimumab; Natalizumab;

D O I：

10.1007/s11894-005-0080-3

中图分类号：

学科分类号：

摘要：

Traditional medications for inflammatory bowel disease are small molecule drugs, most of which were developed for use in other diseases before being found to be efficacious for the treatment of ulcerative colitis or Crohn's disease. Recently, several exciting alternative approaches to the medical treatment of inflammatory bowel disease have been developed. These include biologic, probiotic, and apheresis therapies that offer certain advantages over traditional drug therapy for inflammatory bowel disease. The purpose of this review is to assess the current state of knowledge about novel biologic, probiotic, and apheresis therapies and to analyze how best to incorporate these therapies into evolving management paradigms of inflammatory bowel disease. Copyright © 2005 by Current Science Inc.

引用

页码：485 / 491

页数：6

共 61 条

[11]

Colombel J.F., Ricart E., Loftus Jr. E.V., Et al., Management of Crohn's disease of the ileoanal pouch with infliximab, Am J Gastroenterol, 98, pp. 2239-2244, (2003)

[12]

van der Heijde D., Dijkmans B., Geusens P., Et al., Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT), Arthritis Rheum, 52, pp. 582-591, (2005)

[13]

Brooklyn T., Shetty A., Bowden J., Et al., Infliximab for the treatment of pyoderma gangrenosum: A randomised, double-blind placebo-controlled trial, Gastroenterology, 128, (2005)

[14]

Sandborn W.J., Feagan B.G., Hanauer S.B., Et al., An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial, Gastroenterology, 120, pp. 1330-1338, (2001)

[15]

Feagan B.G., Sandborn W., Baker J.P., Et al., A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease, Aliment Pharmacol Ther, 21, pp. 373-384, (2005)

[16]

Sandborn W.J., Feagan B.G., Radford-Smith G., Et al., CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: A randomised, double blind, placebo controlled trial, Gut, 53, pp. 1485-1493, (2004)

[17]

Stack W.A., Mann S.D., Roy A.J., Et al., Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease, Lancet, 349, pp. 521-524, (1997)

[18]

Schreiber S., Rutgeerts P., Fedorak R.N., Et al., A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease, Gastroenterology, 129, pp. 807-818, (2005)

[19]

Sandborn W.J., Rachmilewitz D., Hanauer S.B., Et al., Infliximab induction and maintenance therapy for ulcerative colitis: The ACT2 trial, Gastroenterology, 128, (2005)

[20]

Rutgeerts P., Feagan B.G., Olson A., Et al., A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: ACT 1 trial, Gastroenterology, 128, (2005)

← 1 2 3 4 5 6 7 →